Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trex
2024-513459-34-00Phase 2Authorised
- Sponsor
- Medical University of Vienna
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of tocilizumab in kidney transplant (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Co-primary endpoint 1 (safety) and Co-primary endpoint 2 (efficacy). Planned start May 2024; status: authorised.
02
Drugs
tocilizumab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2024-513459-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513459-34-00.